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Abstract
Background: Newcastle disease (ND), which is caused by the Newcastle disease virus (NDV), is one of the most
important avian diseases in poultry. Since its discovery in 1926, ND has caused great economic losses to the world
poultry industry and remains a threat to chickens and wild birds. Although a stringent vaccination policy is widely
adopted to control ND, ND outbreaks still occur, and virulent NDV is sporadically isolated from chickens and wild
birds. To study the pathogenesis of ND and provide tools to prevent its prevalence, novel antibody fragments
should be developed. The variable domains of the heavy chain of the heavy-chain antibodies (VHH) are the
smallest naturally occurring antibodies derived from camelid heavy-chain antibodies. The comparatively small size,
high affinity, high solubility, low immunogenicity and ability to bind epitopes inaccessible to conventional
antibodies of VHH make them ideal candidates for a considerable number of therapeutic and biotechnological
applications. However, an anti-NDV VHH has not been reported to date.
Results: In this study, a VHH yeast two-hybrid library was constructed from NDV vaccine immunized C. bactrianus,
and seven VHH fragments to the haemagglutinin-neuraminidase (HN) protein of NDV were successfully screened
and characterized for the first time. These selected VHH clones were all expressed as soluble protein in E. coli. ELISA,
dot blot, immunocytochemistry and pull down results showed that the screened VHHs could interact with NDV
virion, among which five had neutralizing activity. In addition, the seven VHHs could inhibit the haemagglutination
activity of different NDV strains.
Conclusions: We constructed an NDV-immunized VHH yeast two-hybrid library and screened and characterized
seven VHHs targeting NDV HN protein for the first time. The seven VHHs may have great potential for NDV
diagnosis, pathogenesis and therapeutics.
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Background
Newcastle disease (ND), which is caused by the Newcas-
tle disease virus (NDV), is one of the most serious avian
diseases. NDV belongs to the family Paramyxoviridae
and genus Avulavirus. NDV can infect a wide range of
domestic and wild bird species and cause great eco-
nomic losses to the poultry industry [1, 2]. It is an envel-
oped, single-stranded, non-segmented, negative-sense
RNA virus with a genome length of approximately 15 kb
nucleotides that contain six genes encoding for six
structural proteins and two additional proteins [3].
Haemagglutinin-neuraminidase (HN) protein is one of
the major glycoproteins. It forms spike-like structures
on the outer surface of the virion and mediates the
attachment of the virus to the sialic acid-containing re-
ceptors [4]. The HN protein is also an important target
of host immune responses and a major protective anti-
gen. Monoclonal antibodies of the HN protein were
found to neutralize NDV infectivity [5]. Therefore, the
HN protein is considered the most predominant antigen
in the control of NDV.
In the past decades, ND epidemics were effectively
controlled because of widespread vaccination. However,
recent ND outbreaks in vaccinated flocks still caused
damage to the poultry industry, and virulent NDV is
continually isolated from vaccinated chickens [6–9]. A
considerable number of studies indicated that current
vaccines and therapeutic antibody-like biological agents
could not completely stop the transmission of virulent
NDVs [10–12]. Therefore, the development of novel
methods for ND control is necessary.
The variable domains of camelid heavy-chain anti-
bodies (VHH) are the smallest naturally occurring
functional antibody fragments that maintain the antigen-
binding capacity [13, 14]. Their comparatively small size,
monomeric behavior, high stability, high solubility,
powerful penetrability, low immunogenicity, and ability
to bind epitopes inaccessible to conventional antibodies
make VHHs ideal candidates for many therapeutic and
biotechnological applications [15]. Therefore, the screen-
ing and characterization of VHH against NDV have
great importance in ND control, discovery of potential
epitopes, and antigenic variation research.
In this study, a VHH yeast two-hybrid library was suc-
cessfully constructed from inactivated NDV vaccine-
immunized C. bactrianus, and seven HN-targeted VHHs
were obtained after screening. Deduced amino acid se-
quence alignment results indicated that the residues at
position 37, 44, 45 and 47 of the amino acids sequence of
the seven VHHs were also characteristic of a previously
reported VHH, except VHH7. Using prokaryotic expres-
sion vector pHSIE, seven VHHs were expressed as a sol-
uble recombinant protein fused with 6 ×His-SUMO tag in
E. coli. ELISA, dot blot and immnunocytochemistry
results showed that the selected VHHs could specifically
interact with the NDV. Haemagglutination inhibition
assay (HI) showed that the seven selected VHHs could in-
hibit the haemagglutinin activity (HA) of NDV. Further-
more, five VHHs showed neutralizing activity against
virulent NDV. The selected HN-targeted VHHs have po-




La Sota and F48E9 strains of the NDV were used in this
study. The La Sota is a widely used genotype II lento-
genic vaccine strain. While the F48E9 is a standard
genotype IX velogenic strain in China. These two
strains were propagated in the allantoic cavity of 9–11
day-old specific pathogen-free embryonated chicken
eggs. Allantoic fluid was harvested from embryonated
chicken eggs and stored at −70 °C until use.
Cells, yeast strains, and plasmids
DF-1 cells and HEK 293 T cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10 % fetal bovine serum (FBS), 100 U/mL
penicillin, and 0.1 mg/mL streptomycin. Plasmid pHSIE
was kindly provided by Yi Zheng of the Shenzhen Key
Lab of Gene and Antibody Therapy, Tsinghua University.
Y2HGold yeast strain, Y187 yeast strain, pGADT7-Rec
(cloning vector), pGBKT7 (cloning vector), pGADT7-T
(control vector), pGBKT7-Lam (control vector), and
pGBKT7-53 (control vector) were purchased from
Clontech (Japan).
Animal and vaccination
A six-month-old female C. bactrianus was immunized
with a combination of inactivated NDV (La Sota) and
subtype H9 avian influenza (Strain F) vaccine (Qingdao
Yebio Bioengineering Co., Ltd, China) five times at two-
weeks intervals. The administrated dose was based on
the weight ratio between chicken and C. bactrianus.
After vaccination, the humoral immune response was
monitored by HI assay in V-bottom microtiter plates as
previously described [16]. The animal with a strong re-
sponse was bled 20 day after the last immunization.
RNA isolation and VHH amplification
Approximately 70 mL immunized animal blood was
collected 20 day after the last immunization. Lympho-
cytes were isolated with Ficoll-Paque PLUS and stored
at −70 °C until use. Total RNA was extracted from ap-
proximately 107 lymphocytes using the RNeasy Plus
Mini Kit (Qiagen, Germany), and the first-strand cDNA
was synthesized using the HiScript 1st Strand cDNA
Synthesis Kit (Vazyme, China) with Oligo-dT primers.
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The first round of polymerase chain reaction (PCR) was
performed with synthesized cDNA as a template using
the primers V-F and V-R (Table 1) to amplify a 900 bp
fragment encoding VH-CH1-CH2 and a 600 bp frag-
ment encoding VHH-CH2. The 400 bp fragment of
VHH was amplified through a second round of PCR
using the gel-purified 600 bp fragment from the first
round of PCR as a template with primers VHH-F and
VHH-R (Table 1). The 400 bp VHH fragment was ex-
cised from the gel and purified using a gel extraction kit
(OMEGA, USA).
Yeast two-hybrid library construction and quality
evaluation
Y187 yeast competent cells were prepared using the
Yeastmaker Yeast Transformation System 2 kit accord-
ing to the user manual. About 20 μL of VHH fragments
(4–5 μg) and 3 μg of linearized pGADT7-Rec were co-
transformed into Y187 yeast cells to construct the VHH
Y2H library according to the Make Your Own “Mate &
Plate™” Library System User Manual (Clontech, Japan).
To determine the complexity of the library, 100 μL of 1/
10, 1/100 and 1/1000 dilutions of transformed cells was
spread on SD/–Leu (synthetically defined medium
lacking leucine) 100 mm agar plates. After incubation at
30 °C for 3 −4 days, numbers of independent colonies
that appeared on the dilution plates were counted to
calculate library capacity. To determine the titer of the
constructed VHH yeast two-hybrid library, 100 μL of
library aliquot was taken out and serially diluted to
1/100, 1/1000, 1/10000, and 1/100000. The library titer
was calculated according to the colonies appearing.
Simultaneously, 47 random clones were picked for in-
sertion diversity identification by PCR using the univer-
sal primers 3’AD and T7 (Table 1). Ten positive clones
produced a PCR product of approximately 400 bp were
chosen randomly for gel-purification and sequencing.
The sequence results were analyzed using the NCBI
BLASTP program to verify the signature of the VHH
insertions.
Yeast two-hybrid screen
To obtain HN protein targeting VHH antibodies from
yeast two-hybrid library, the bait protein with truncate
coding sequences of HN (49–577 aa) from La Sota strain
was cloned into the BamH I and Sal I sites of pGBKT7
and expressed as a fusion to the yeast GAL4 DNA-BD.
Before screening, the bait protein was tested against the
autoactivity and toxicity of HN. Then, a concentrated
Y2HGold (pBD-HN) culture with 1 mL of Y187 (pAD-
VHHs) yeast two-hybrid library aliquot was mixed for
mating according to the Matchmaker™ Gold Yeast Two-
Hybrid protocol (Clontech, Japan). Seventy 150 mm
DDO/X/A (double dropout medium lacking tryptophan
and leucine and supplemented with X-α-Gal and Aureo-
basidin A) plates were used to screen the clones after
mating for 3−5 days. All blue colonies that appeared on
DDO/X/A plates were then patched out and allowed to
grow on QDO/X/A (quadruple dropout medium lacking
adenine, histidine, tryptophan and leucine and supple-
mented with X-α-Gal and Aureobasidin A) plates. The
blue colonies were screened twice on QDO/X/A plates
to rescue the additional library plasmids and eliminate
the false positives. The bait plasmid (pBD-HN) and res-
cued prey plasmid (pAD-VHH)s were co-transformed
into Y2HGold yeast strain to confirm the interactions in
yeast cells. The bait plasmid (pGBKT7-53 or pGBKT7-
Lam) was co-transformed into Y2HGold with the prey
plasmid (pGADT7-T) to serve as positive and negative
controls, respectively. The rescued genuine positive AD/
library VHH inserts were further sequenced and aligned
using the NCBI BLASTP program.
Expression and purification of VHH
The screened VHH fragments were amplified with the
primers VHH-EF and VHH-ER (Table 1) and cloned into
plasmid pHSIE using the BamH I and Sal I restriction
enzyme sites for fusion with the 6 × His-SUMO tag at
the N-terminus. After sequencing, the recombinant ex-
pression plasmids were transformed into E. coli Rosetta
(Novagen) and incubated at 37 °C overnight. Subse-
quently, 1 mL of an overnight culture of cell was inocu-
lated into 100 mL LB ampicillin broth and further
incubated at 37 °C for 3–4 h (OD600 reached 0.4–0.6).
The culture was induced by 0.5 mM isopropyl-D-
thiogalactopyranoside (IPTG) at 30 °C for 5 h. The cell
pellets were collected to check the expression of VHH
antibodies by 12 % sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE). The VHH
Table 1 Primers used in this study













aLetters in bold italics is the homologous arms
Underlined nucleotides in primers representing the restriction enzyme sites
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antibodies were further purified using Talon Metal Affin-
ity Resins (Clontech) according to the user manual and
eluted with phosphate-buffered saline (PBS) containing
250 mM imidazole.
HI assay
The specific interaction between purified VHH and HN
was tested using HI assay as previously described [16].
Briefly, 25 μL of PBS containing 4 HA units of antigen
was incubated in a V-bottom 96-well plate with 25 μL of
twofold serially diluted VHHs at room temperature for
40 min. Subsequently, 50 μL of 1 % suspension of
chicken erythrocytes was added. The mixture was incu-
bated at room temperature for 30 min. The purified bac-
terial lysate of bacteria transformed with an empty
pHSIE vector or an anti-NDV positive serum were used
as negative and positive controls, respectively. Agglutin-
ation of erythrocyte in the plate was scored. HI assay
was performed using different strains. Titers were calcu-
lated as the highest reciprocal dilutions that completely
inhibited haemagglutination. All tests were performed
twice.
ELISA
To verify the interaction between the selected VHH and
NDV, the NDV La Sota strain was coated onto Maxisorp
96-well plates (Nunc) in Na2CO3 (0.05 M, pH 9.6) over-
night at 4 °C with 100 μL/well. The purified 6 ×His-SUMO
tag and anti-NDV negative serum served as the negative
control, and the anti-NDV positive serum (kept by our la-
boratory) served as the positive control. In the following,
the plates were blocked with 5 % skimmed milk–PBS with
0.05 % Tween 20 (PBST) for 1 h at 37 °C. After rinsing for
five times with PBST, 100 μL diluted VHH (200 μg/mL)
was added into each well for 2 h further incubation
at 37 °C in triplicate. Subsequently, the wells were rinsed
five times with PBST, and 100 μL of horseradish peroxid-
ase (HRP)-conjugated Anti His-Tag Mouse Monoclonal
Antibody (CWBIO, Beijing) was added at a 1:3000 dilu-
tion for 1 h at 37 °C. whereas, the positive control wells
were treated with HRP-conjugated goat anti-chicken anti-
body (Bioss, Beijing). After washing with PBST for five
times, the reaction was developed by adding 100 μL tetra-
methylbenzidine (TMB) and stopped by adding 50 μL 2 N
H2SO4 after 20 min of incubation at room temperature.
The absorbance was read using a microplate reader at
450 nm (Bio-Rad).
Dot blot analysis
Dot blots were performed according to western blot pro-
tocols, except that sucrose-gradient centrifugation puri-
fied NDV were spotted on a polyvinylidene fluoride
membrane (0.45 μm, Millipore, USA) without preceding
gel electrophoresis. The membrane was blocked with
5 % skimmed milk for 2 h at room temperature and then
washed twice with TBST (Tris buffered saline containing
0.5 % Tween 20). The purified VHHs (200 μg/mL) were
applied at 1:100 dilution. After 2 h incubation at 37 °C,
the membrane was washed four times and incubated
with HRP-conjugated anti His-Tag mAb (1:5000 dilution)
for 1 h at 37 °C. After four further washes with TBST, the
immunoreactive was visualized with cECL Plus Western
blotting detection reagent (CWBIO). The anti-NDV posi-
tive serum and negative serum were used as positive and
negative controls.
Pull down
To determine the interaction between VHH and HN pro-
tein, HEK 293 T cells were seeded in a 6 wells plate. The
next day, 293 T cells were transfected with pCAGGS-HN
plasmid or pCAGGS empty plasmid using lipofectamine
2000 reagent (invitrogen). Cells were put on ice 36 h post
transfection, washed once with PBS and subsequently
lysised with 150 μL/well RIPA buffer for 10 min. The
lysate was centrifugated for 5 min at 13000 rpm to
remove cell debris. The supernatant was used as cell
derived HN protein.
1000 μL of the 293 T-HN lysate was incubated with
80 μg VHH, 500 μL talon Metal affinity resin (Clontech)
and 4 mL PBS for 2 h at 4 °C. Talon matrix was washed
twice with 4 mL PBS. 300 μL sample buffer was added,
boiled for 10 min and separated with SDS-PAGE. The
gel was blotted and the membrane was immunolabeled
with guinea pigs anti-HN polyclonal antibody (prepared
by our lab), HRP goat anti-Guinea pig IgG (ABclonal)
and HRP-conjugated anti His-Tag mAb (CWBIO).
Neutralizing assay
Virus neutralization (VN) assay was conducted to con-
firm the neutralizing activities of the selected VHH.
Briefly, 50 μL of the purified VHH (200 μg/mL) was
twofold serially diluted and then incubated for 1 h at
37 °C with 100 TCID50 of the NDV F48E9 strain in
DMEM. After incubation, the DF-1 monolayer of cells
grown in 96-well tissue culture plates was infected with
the virus-VHH mixture. After absorption at 37 °C for
1 h, the cell cultures were washed twice with PBS. Fresh
DMEM with 2 % FBS was subsequently added. The cell
cultures were further incubated for 36 h at 37 °C. Syn-
cytium formation of the infected cells was observed in
each well. Virus- and mock-infected cells were used as
controls. Anti-NDV positive and negative serum were
also included as positive and negative controls, respect-
ively. Neutralizing activity was primarily confirmed by
the absence of syncytium formation.
To further quantify the neutralization activity, super-
natants of cell cultures were harvested at 36 h post
Gao et al. BMC Veterinary Research  (2016) 12:39 Page 4 of 13
inoculation, serially diluted, and assayed for virus titer
using Reed-Muench method [17].
Immunocytochemistry assay
To verify the specific intracellular binding activity between
selected VHHs and NDV virus, LaSota-infected DF-1 cells
and mock control were grown on 24-well dishes for the
immunoperoxidase assay. After 48 h, the cells were fixed
with 4 % paraformaldehyde on 24-well dishes and were
permeabilized with PBS-0.5 % Triton X-100. The fixed
cells were incubated with blocking solution (2 % BSA)
followed by the VHH for 2 h at 37 °C. Subsequently, the
treated cells were incubated with horseradish peroxidase
(HRP)-Conjugated Anti His-Tag Mouse Monoclonal
Antibody (CWBIO, Beijing) at a 1:4000 dilution for 1 h at
37 °C. The detection of the antigen was carried out using
DAB Kits (CWBIO). At last, the nuclear of cells were
stained by hematoxylin. The results were examined under
an inverted light microscope.
Statistical analysis
Statistically significant differences in HI assay and ELISA
assay among VHHs were evaluated using Student’s t test
with the Prism 5.0 (Graph Pad Software, Inc., San Diego,
CA). The calculated P values of < 0.05 were considered
statistically different.
Ethics statement
C. bactrianus was grown in a farm of the Gobi Desert,
northwest of China, with feed and water administrated
ad libitum. The inactivated vaccine immunizations and
jugular vein blood sampling were performed in strict
accordance with the Animal Ethics Procedures and Guide-
lines of the People's Republic of China. The study was ap-
proved by the Animal Ethics Committee of Northwest
A&F University, Shaanxi Province, China. In this study,
the owner of the C. bactrianus gave us permission to ex-
periment on the animal, which was returned to the owner
after the completion of the experiment. We unequivocally
state that this work did not involve any ethical issues.
Results
Anti-NDV specific HI antibody titer of camel serum
Approximately 5 mL blood of was aseptically collected
from the immunized animal 14 day after second and
fifth immunization to evaluate the humoral response.
The blood was allowed to clot to extract the serum.
Then, the serum was used for HI assay with 4 HA units
of La Sota strain as the antigen, as described in the OIE
manual [16]. The anti-NDV HI antibody titer was 10
log2 (Additional file 1: Table S1).
VHH amplification and yeast two-hybrid library
construction
As shown in Additional file 1: Figure S1A, a 900 bp frag-
ment and a 600 bp fragment were successfully amplified
with the primers V-F and V-R in the first round of PCR.
Then, the 400 bp VHH fragment was amplified using the
gel-purified 600 bp fragment from the first round of PCR
as the template with the primers VHH-F and VHH-R
through a nest PCR (Additional file 1: Figure S1B).
During the library construction, 4.4 μg gel-purified
VHH fragment was co-transformed with 3 μg Sma I
linearized pGADT7-Rec plasmid into Y187 competent
cells for recombination. Three parameters were used to
evaluate the quality of the yeast two-hybrid library: library
capacity, library titer, and percentage of library clones that
contain insertions. Results of the calculations were as fol-
lows: the library capacity was 1.25 × 107(Additional file 1:
Figure S3A), and the library titer was 3.45 × 108 cfu/
mL(Additional file 1: Figure S3B). A total of 45 clones in
47 randomly selected clones had 400 bp VHH bands after
PCR identification with primers T7 and 3’AD (Additional
file 1: Figure S2); thus, the percentage of library insertion
rate was approximately 96 %. Ten PCR positive clones
were chosen randomly for sequencing. The results showed
that these clones were all unique sequences, indicating di-
versity of the library (Additional file 1: Figure S4). Thus,
the quality of the VHH yeast two-hybrid library met the
demand for screening.
Bait construction
The truncate HN gene was amplified from the cDNA of
the La Sota strain using the primers HN-F and HN-R.
The amplified products were approximately 1600 bp
(Additional file 1: Figure S5A). Subsequently, the ampli-
fied fragments were subcloned into vector pGBKT7 by
BamH I and Sal I digestion and ligation (Additional file 1:
Figure S5B). Clones were verified by sequencing. Finally,
the pGBKT7-HN was transformed into Y2HGold yeast
strain as a bait.
Selection of HN-specific VHH antibody fragments
Before screening, no autoactivator activity of the BD-HN
was confirmed in yeast (Lane A, Fig. 1). When zygotes
formed after mating the Y2H Gold (pBD-HN) and the
Y187 yeast library (pAD-VHHs), the mating products
were spread on the DDO/X/A plates for incubation at
30 °C for 3–5 days. Hundreds of blue yeast colonies
were selected. However, only seven clones were recov-
ered after two rounds of screening on the QDO/X/A
plates. To verify the positive interactions between VHHs
and HN protein in yeast, the prey plasmid isolated from
the seven clones were co-transformed with the bait plas-
mid (pBD-HN) or the pGBKT7 empty vector. The co-
transformation results showed that all the seven clones
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rescued from the QDO/X/A plates were genuine positive
clones (Lanes B–H, Fig. 1). The sequencing results
showed that the seven positive clones were of different
clone origins and that the insertions were homologous
to the properties of camel VHH, except VHH7 (Fig. 2).
Expression and purification of VHH
Seven VHH fragments were cloned into pHSIE using
the BamH I and Sal I restriction enzyme sites for ex-
pression and purification (Additional file 1: Figure S6).
As 6 × His-SUMO tag was fused with the VHH frag-
ments at the N-terminus, the recombinant VHHs were
purified using Talon Metal Affinity Resin (Clontech).
After electrophoresis on a 12 % SDS-PAGE, the 6 × His-
SUMO-VHHs fusion proteins exhibited bands that were
approximately 30 kDa (Lanes 1–7, Fig. 3). All VHH frag-
ments were solubly expressed.
HI titer of VHH
The HI assay is an important and convenient method
widely used for antibody detection. As shown in Table 2,
all selected VHHs shared an HI titer ≥ 4 log2 except
VHH2, and the HI titer of the VHH was significantly
lower than that of the positive serum. The HI titers,
which were tested using different NDV strains as 4
HAU, were slightly different.
ELISA
Indirect ELISA was conducted to verify the specific inter-
action between the VHH and the NDV. For the plate
coated with the NDV La Sota (TCID50 = 10
-8.17/0.1 mL),
the optimized coated concentration was 1:20. ELISA re-
sults showed that all the selected VHHs could react with
the NDV virions (Fig. 4). The OD450 of the seven VHHs
were significantly stronger than the negative controls
(P < 0.05; Fig. 4). The reaction in the wells of the
negative control was very weak (OD450 < 0.10). All tests
were performed three times.
Dot blot
The seven VHHs and positive serum could bind native
NDV virion (Fig. 5, a-g and p). While the positive serum
Fig. 1 Interaction between HN and VHH in yeast. The white clones in lane A showed that the bait(pBD-HN) has no autoactivator activity in yeast.
When pBD-HN and 7 positive pAD-VHH were cotransformed into Y2HGold yeast strain, all cotransformants turned blue on DDO/X/A and QDO/X/
A plates after incubation. At the same time, the pGBKT7-p53 and pGADT7-T co-transformants was used as positive control, whereas pGBKT7-Lam
and pGADT7-T co-transformants was used as negative control
Fig. 2 Deduced amino acid alignment of 7 selected anti-HN VHH. Deduced amino acid sequences were analyzed according to the Kabat numbering [54].
The dots indicate the same sequences compared with VHH1. Differences in the sequences are pinked, and the dash represent the missing sequences. Two
hallmark Cys residues are labeled by the thick-line boxes. The four conservative hallmark residues of VHH in FR2 are labeled by the dotted line boxes
Gao et al. BMC Veterinary Research  (2016) 12:39 Page 6 of 13
and VHHs could not bind allantoic fluids without NDV
(Fig. 5, n1 and n2). This result suggested that the VHHs
could recognize NDV.
Pull down
Using VHH6 as model, the interaction between VHH
and HN protein was detected by His-tag Pull down
assay. As shown in Fig. 6, VHH6 were able to pull down
the HN protein from a HN transfected 293 T cell lysate
and not from a pCAGGS empty vector transfected
293 T control cell lysate. The result indicated that these
VHH6 could interact with HN protein.
Neutralizing assay
Neutralizing assay was performed to evaluate the
neutralization ability of the VHHs against F48E9 infec-
tion. As shown in Fig. 7, the five VHHs (VHH3, VHH4,
VHH5, VHH6, and VHH7) had neutralizing activity to
inhibit the replication of F48E9 on the DF-1 cell as there
was no syncytia appeared at 24 h post-inoculation, al-
though the neutralizing titer was significantly lower than
the positive control (VHH ≤ 22,positive serum > 27).
However, some syncytia can be observed on cells at 36–
72 h post-inoculation in experiment wells, while positive
serum can effectively inhibit the infection of virus. The
negative control showed no neutralizing activity.
VHH6 was picked out as an example to quantify
neutralization activity. Thirty-six hour post-inoculation,
supernatants were harvested and tested for virus titer.
Results indicated that virus propagation was significantly
inhibited by the VHH6 (Fig. 8).
Detection of NDV-infected cells by immunocytochemistry
Using VHH6 as model, the intracellular specificity and
binding affinity of selected VHHs were further detected
by immunocytochemistry. As shown in Fig. 9, the strong
cytoplasm brownish staining was specifically appeared in
NDV-infected DF-1 cells (0.01 MOI) group but not in
the mock control. These results indicated the feasibility
of detection intracellular NDV antigen by using selected
VHHs.
Discussion
The HN protein, which is an important multifunctional
surface glycoprotein consists of a cytoplasmic domain, a
transmembrane region, a stalk region and a globular head,
possesses both HA and NA activities and all the antigenic
sites [18]. HN protein binds to the sialic acid receptor me-
diating virus attachment to cells and promotes the fusion
activity of the F protein, allowing the virus to penetrate
the cell surface, and receptor-destroying activity to facili-
tate virus budding. The polyclonal or monoclonal anti-
body targeting HN protein has been reported to neutralize
the infectivity of the NDV. Therefore, the HN protein is
an ideal target for NDV treatment and many therapeutic
reagents have been developed against HN protein, includ-
ing hyper-immune sera, egg yolk antibody, and monoclo-
nal antibodies [19–23]. However, anti-HN VHH have not
been reported yet.
A phage display library is widely used to select scFv and
VHH from a considerable number of interested targets,
such as Influenza A virus M2 ion channel, chemokine re-
ceptor CXCR4, and murine ADP-ribosyltransferase C2
[24–26]. Acquiring pure antigen is the premise to panning
a phage library. However, not all antigens are easy to
prepare, and the process is usually time consuming and
laborious. Yeast two-hybrid technology is a useful
tool to study protein-protein interactions, including
Fig. 3 SDS-PAGE of purified VHH. All seven purified VHH were
separated on 12 % SDS-PAGE gels. And the gel was stained with
coomassie blue. Lane 1 to 7 represent VHH 1 to VHH 7, respectively.
The molecular weight of the 6 × His-SUMO-VHH fusion proteins were
about 33 kDa in size
Table 2 HI titer of selected VHH
Strain Origin Genotype HI titer (X Log2)
VHH1 VHH2 VHH3 VHH4 VHH5 VHH6 VHH7 Posivtivea Negativeb
F48E9 Chicken IX 4 1 5 5 5 5 4 9 0
LaSota Chicken II 4 2 4 6 6 4 4 8 0
YuLin Chicken IX 4 1 5 5 5 5 5 8 0
Dove Chicken IX 4 1 4 4 4 5 4 6 0
W2 Chicken VII 6 1 5 4 4 5 4 6 0
aRepresent anti-NDV positive serum
bRepresent sumo-tag
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antibody-antigen interaction. A previous study reported
the feasibility of using yeast two-hybrid to screen high af-
finity VHH against the targeted protein in vivo, which
avoid the time-consuming antigen preparation [27]. In the
present study, in order to avoid HN protein preparation,
the truncate HN gene was cloned into bait plasmid for fu-
sion expression with binding domain (BD) of Gal4. Then
the autoactivity and toxicity of the bait protein were
assessed, result showed that HN-BD had no autoactivity
and toxicity. Whereas, the expression level of HN-BD in
yeast Y2H Gold cells was relatively low (Additional file 1:
Figure S7). The low expression level may be ascribed to
the following reasons. On the one hand, HN protein con-
tains 12 cysteines, the Y2H yeast strain might have prob-
lems in the production of proteins with multiple cysteine
bridges. On the other hand, the host yeast cells, although
a eukaryote, is distant from human, mamalian, and higher
eukaryotic organisms. So, sometimes the conditions in
yeast cells may not allow the proper folding or posttrans-
lational modifications required for some proteins. Al-
though in a low expression level, after screening the VHH
yeast two-hybrid library with the truncate HN bait pro-
tein, seven VHHs were successfully obtained for the first
time. HI assay, dot blot, ELISA, immunocytochemistry
and pull down results indicated that the purified VHHs
could react with the NDV virions or HN protein.
The VHH is generated from a V-D-JH gene rearrange-
ment using a specific set of V gene segments, which exist
in the germline of the camelid genome [28]. At least four
distinct VHH subfamilies have been defined, but they all
share several crucial amino acid substitutions in the frame-
work 2 region, namely, Val37-Phe/Tyr, Gly44-Glu/Gln,
Leu45-Arg, and Trp47-Gly/Phe/Leu (Kabat numbering),
which increase the hydrophilicity of the VHH. These VHH
hallmark residues compensate for the possible instability,
hydrophobicity, and aggregation tendency of VHH because
Fig. 4 Detection of interaction between selected VHH and NDV virion by ELISA. Microplates were coated with NDV La Sota virion (TCID50 10
-8.17/
0.1 mL, 1:20 dilution). The 7 selected VHH (200 μg/mL) were diluted at different concentrations, and anti-NDV positive serum (Positive control),
negative serum (Negative control 1) and 6 × His SUMO tag (Negative control 2) were used as positive and negative control. The value of absorbance
at 450 nm indicate the reactivity between VHH and NDV. And the data represents the average of 3 wells
Fig. 5 Detection of interaction between VHH and NDV virion by Dot blot. Purified NDV (a-p) or allantoic fluid (n1 and n2) were spotted on a
PVDF membrane for blot. VHHs binding were visualized using HRP labeled anti-His Mabs While positive serum was visualized using HRP labeled
anti-chicken antibody. a-g represent VHH1-VHH7; p represent positive serum; n1 represent VHHs (VHH 1 to VHH 7); n2 represent positive serum
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of the lack of VL domains [13, 29, 30]. The variable
domains of antibody consist of four framework regions
(FRs) and three complementary determining region
(CDRs) [31, 32]. The amino acid sequences of the FR are
generally constant and not easily changed. The amino acid
sequences of the CDR are highly variable, and they
determine the antibody specificity and diversity [33].
In this work, we screened seven VHH antibodies
from C. bactrianus for the first time. The sequence
alignment results showed that the four conservative
hallmark residues of the VHH in FR2 were in accord-
ance with previous reports [34], except for VHH7. By
analyzing the alignment results we also found that
the sequence differences of these VHHs were mainly
localized in the CDRs as others reported [28, 30].
To avoid VH contamination in VHH library, usually
two rounds PCRs are performed. The first is used to
discriminate VH (VH-CH1-hinge-CH2) from VHH
(VHH-hinge-CH2) based on amplicon sizes which differ
by 300 bp in length. The second is used to amplified VHH
from the short amplicons (VHH-hinge-CH2) with primers
annealing at the codons of FR1 and FR4. Afterward VHH
fragments are cloned for library construction and selec-
tion. In the present study, two successive PCRs were per-
formed during IIama VHH library construction to select
for VHH sequence rather than VH. After screening, seven
positive clones were obtained. However, sequence align-
ment result showed that especially VHH7 did not contain
the hallmark residues in FR2 that are typical of VHHs as
described in previous reports [34]. The presence of vari-
able single domains that seem to originated from VH have
been repeatedly identified together with canonical VHHs
in immune libraries [35, 36]. Monegal reported that single
domains antibodies with VH hallmarks could be positively
Fig. 6 Validation of VHH against cell derived HN protein. Pull down
of cell derived HN protein from pCAGGS-HN transfected 293 T cells
lysate or pCAGGS empty vector transfected 293 T cells lysate using
VHH6 with talon metal affinity resin. Western blot with anti-HN
polyclonal antibodies and anti-his tag mAb
Fig. 7 Syncytium formation of DF-1 cell treated with anti-HN VHH. Virus neutralizing assay was performed on DF-1 cells. Syncytium formation was
observed under a microscope 36 h post inoculation. a 6 × His-SUMO tag treated. b VHH treated. c Anti-NDV positive serum treated. d Negative
serum treated. e Mock
Fig. 8 The determination of the effects of VHH on the virus
production. Virus titer in the culture supernatants was measured at
different VHH concentration by Reed-Muench method
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selected during panning of VHH libraries [37]. These
unexpected VH sequences could result from PCR
crossover between VHH and VH fragments or re-
arrangement of classical VH domains to IgG2 or IgG3
constant regions [38].
To investigate the reactivity of the selected VHHs with
the NDV, ELISA, HI, dot blot and immunocytochemistry
were performed. As shown in Fig. 4, all the selected
VHHs could specifically interact with the NDV La Sota
strain, and the reactivity were significantly stronger than
negative controls (P < 0.05). The ELISA results suggested
that all the selected VHHs could interact with NDV vi-
rions. HI assay is a convenient method widely used for
the detection of interactivity between antibody and HN
protein. As shown in Table 2, all VHHs could inhibit the
HA activity of different strains, but they shared different
HI titers against different strains. The different HI titers
indicated that antigenic variations exists among different
NDV strains, which is consistent with previously re-
ported [39–41]. Whereas, the HI titers of VHHs were
significantly lower than that of the positive serum. Previ-
ously, it has been demonstrated that HA activity was de-
termined by multiple sites on HN protein [42–45].
Therefore, the lower HI titer of the VHH compared with
the positive serum may be attributed to the fact that
each selected VHH only recognized a limited number of
epitopes associated with the HA activity. Moreover, the
small size of the VHH may not be sufficient to form a
steric hindrance that will completely block the active site
involved in HA activity when binding on the HN. Multi-
merization or polyvalence of the VHH may be a promis-
ing method to enhance its function in the future.
Using monoclonal antibodies, seven antigenic sites have
been identified in the HN glycoprotein and formed a
linked continuum, in the order of sites 4-14-1-12-1-23-3
[5, 46]. And most of the HN epitopes were conformational
epitopes, only one linear epitope was revealed (residues
345 to 353 aa) [5]. In the present study, we proved that all
the selected VHHs could interact with NDV through dot
blot, ELISA, and HI. At the same time, the VHH were also
able to pull down HN protein from cell lysate. However,
the reactivity were not detected using western blot (data
not shown). These results suggested the VHHs might
recognize conformational eipitopes rather than linear
epitopes. The findings are in accordance with Iorio’s that
most of the selected monoclonal antibodies bind to HN,
but only when it has been neither reduced nor boiled [47].
Which epitopes are recognized by our VHHs and do the
epitopes different from previously reported need further
investigation.
The NDV HN antibodies can be separated into two
groups with respect to their mechanism of neutralization,
namely, those that prevent receptor recognition and those
that do not [46]. And evidence for a multiple-antibody
mechanism of neutralization has been gathered in several
systems with both polyclonal and monoclonal antibodies
Fig. 9 Immunocytochemistry analysis with VHH6. A and a, mock-infected DF-1 cells; B and b, LaSota infected DF-1 cells. All cells were examined
under an inverted light microscope (40×). The expression of NDV HN glycoprotein is visualized as a brown color in the cytoplasm, and cell nuclei
stained with hematoxylin are shown in blue in the DF-1 cells
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[48]. In the present study, as shown in Fig. 7, five of the
seven VHHs displayed neutralizing activity against the
virulent NDV F48E9, but the neutralizing titers were sig-
nificantly lower than that of positive serum. Some syncytia
could be observed on cells at 36–72 h post-infection (data
not shown). Iorio reported that complete neutralization of
NDV required monoclonal antibodies to different sites of
HN glycoprotein [49]. So the neutralizing activity of a sin-
gle VHH may be limited. Apart from the above reason,
the following aspects might be also account for the rela-
tively poor neutralizing activity: 1) Antigenic difference
exist between LaSota strain and F48E9 strain (Table 2)
lead to the low antibody binding activity. 2) The epitopes
recognized by these VHH were not the crucial region for
the blockage of virus. Therefore, we will attempt to
identify the epitopes recognized by these selected VHHs
in our future work. 3) The antibodies targeting fusion
protein (F protein) are reportedly more effective in pre-
venting virus infection than the antibodies targeting the
HN protein [50–53]. So the screening of the VHH target-
ing F protein or other viral proteins is an alternative way.
4) As mentioned previously, we presume that the smaller
size of the VHH could enhance its tissue penetration and
make it bind some cryptic epitopes. However, on the con-
trary, the smaller size may be unable to fully occupy the
targeting site or form a steric hindrance to prevent virus
infection. The multimerization of the selected VHHs may
be a mechanism to enhance their function.
Conclusions
In this study, we constructed a VHH yeast two-hybrid li-
brary. After two rounds of screening, seven VHHs tar-
geted to HN protein were selected and characterized for
the first time. These selected VHHs can specifically
interact with the HN protein and inhibit the HA activity
of the NDV. Most VHHs also showed a neutralizing ac-
tivity. These VHHs have great potential for application
in NDV diagnosis, therapy, and pathogenesis. Moreover,
the VHHs screened on the basis of the yeast two-hybrid
may be an effective tool to examine the mechanism of
ND pathogenesis and vaccination.
Additional file
Additional file 1: Table S1. Humoral immune response after
immunization. Sera from IIama was collected, two-fold diluted and tested
by HI using LaSota as antigen. Figure S1 Amplification of VHH through a
nested PCR. (A) First round PCR to separate VH from VHH. The upper 900
bp bands represent the VH-CH1-Hinge-CH2 of conventional Abs (lane 1–8).
The lower 600 bp bands represent the VHH-Hinge-CH2 of HCAbs (lane 1–8).
(B) VHH amplified through nested PCR using 600 bp fragment recovered
from first round PCR as template (lane 1–4). M in A and B was the DL2000
DNA marker. C in A and B represent the negative control. Figure S2 PCR
identification of inserted VHH. 47 clones were randomly picked to
determine the library functional diversity by PCR using universal primers T7
and 3’AD (Table 1). Meanwhile, Sterile water was used as negative controls.
45 clones have amplified the 500 bp VHH fragments (lane 1–47), while
negative templates control haven’t amplified any bands (lane C). M indicated
the DL2000 DNA marker. Figure S3 Detection of library capacity and library
titer. (A) 10-3 dilution plating of the transformed cells calculated a library
capacity of 1.25 × 107 independent clones. (B) 10-5 dilution plating of the
cultured library indicated a library titer of 3.45 × 108 cfu/mL. Figure S4
Deduced amino acid aligment of 10 random picked VHH. Deduced amino
acid sequences were analyzed according to the Kabat numbering. Differences
in the sequences are pinked, and the dash represent the missing sequences.
Two hallmark Cys residues are labeled by the thick-line boxes. The four
conservative hallmark residues of VHH in FR2 are labeled by the dotted line
boxes. Figure S5 pGBKT7-HN bait plasmid construction. (A) PCR was carried
out to amplify a truncate HN gene (without transmembrane region) from La
Sota strain. M, 5000 DNA marker. 1, Truncate HN. C, Negative control. (B) A
truncate HN was cloned into pGBKT7 through BamH I and Sal I. M, 5000
DNA marker. 1, Double restriction enzyme digestion of pGBKT7-HN. Figure
S6 pHSIE-VHH plasmid construction. (A) 7 positive VHH fragment were
amplified from recovered positive clones containing pGADT7-VHH by PCR. M,
5000 DNA marker. 1–7, VHH 1–7. C, Negative control. (B) Double restriction
enzyme digestion of pHSIE-VHHs. M, 5000 DNA marker. 1–7, pHSIE-VHH 1–7.
Figure S7 Western blot analysis of bait protein expression. 2 mL of
Y2HGold(pGBKT7-HN) culture liquid was extracted using yeast protein
extraction reagent (Takara). c-Myc tag monoclonal antibody (1:4000 dilution)
was used as first antibody and HRP-labeled goat anti-mouse antibody
(1:5000) was used as second antibody. The immunoreactive was visualized
with cECL Plus Western blotting detection reagent (CWBIO). (DOC 1129 kb)
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